Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 3
2015 1
2016 1
2018 4
2019 2
2020 4
2021 3
2022 2
2023 2
2024 1
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium.
Coens C, Pe M, Dueck AC, Sloan J, Basch E, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Devlin N, Dorme L, Flechtner HH, Gotay C, Griebsch I, Groenvold M, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Musoro JZ, O'Connor D, Oliver K, Piault-Louis E, Piccart M, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Taphoorn MJB, Velikova G, Bottomley A; Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data Consortium. Coens C, et al. Among authors: musoro jz. Lancet Oncol. 2020 Feb;21(2):e83-e96. doi: 10.1016/S1470-2045(19)30790-9. Lancet Oncol. 2020. PMID: 32007209 Free article. Review.
Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types.
Musoro JZ, Coens C, Sprangers MAG, Brandberg Y, Groenvold M, Flechtner HH, Cocks K, Velikova G, Dirven L, Greimel E, Singer S, Pogoda K, Gamper EM, Sodergren SC, Eggermont A, Koller M, Reijneveld JC, Taphoorn MJB, King MT, Bottomley A; EORTC Melanoma, Breast, Head and Neck, Genito-urinary, Gynecological, Gastro-intestinal, Brain, Lung and Quality of Life Groups. Musoro JZ, et al. Eur J Cancer. 2023 Jul;188:171-182. doi: 10.1016/j.ejca.2023.04.027. Epub 2023 May 7. Eur J Cancer. 2023. PMID: 37257278 Free article.
Single-arm studies involving patient-reported outcome data in oncology: a literature review on current practice.
Liu L, Choi J, Musoro JZ, Sauerbrei W, Amdal CD, Alanya A, Barbachano Y, Cappelleri JC, Falk RS, Fiero MH, Regnault A, Reijneveld JC, Sandin R, Thomassen D, Roychoudhury S, Goetghebeur E, le Cessie S; SISAQOL-IMI Work Package 3. Liu L, et al. Among authors: musoro jz. Lancet Oncol. 2023 May;24(5):e197-e206. doi: 10.1016/S1470-2045(23)00110-9. Lancet Oncol. 2023. PMID: 37142381 Review.
Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review.
Pe M, Dorme L, Coens C, Basch E, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dirven L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Griebsch I, Groenvold M, King M, Koller M, Malone DC, Martinelli F, Mitchell SA, Musoro JZ, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Sloan J, Velikova G, Bottomley A; Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data Consortium (SISAQOL). Pe M, et al. Among authors: musoro jz. Lancet Oncol. 2018 Sep;19(9):e459-e469. doi: 10.1016/S1470-2045(18)30418-2. Lancet Oncol. 2018. PMID: 30191850 Free article.
Measuring quality of life in clinical research - Part 1.
Ranganathan P, Musoro JZ, Pramesh CS. Ranganathan P, et al. Among authors: musoro jz. Perspect Clin Res. 2025 Jul-Sep;16(3):162-165. doi: 10.4103/picr.picr_179_25. Epub 2025 Jul 8. Perspect Clin Res. 2025. PMID: 40718891 Free PMC article.
Corrigendum to "Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trials" [Lung Cancer 167C (2022) 65-72].
Koller M, Musoro JZ, Tomaszewski K, Coens C, King MT, Sprangers MAG, Groenvold M, Cocks K, Velikova G, Flechtner HH, Bottomley A. Koller M, et al. Among authors: musoro jz. Lung Cancer. 2022 Sep;171:126. doi: 10.1016/j.lungcan.2022.05.006. Epub 2022 May 20. Lung Cancer. 2022. PMID: 35606221 Free article. No abstract available.
Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials.
Gamper EM, Musoro JZ, Coens C, Stelmes JJ, Falato C, Groenvold M, Velikova G, Cocks K, Flechtner HH, King MT, Bottomley A; EORTC Genito-Urinary Tract Cancer Group and Quality of Life Groups. Gamper EM, et al. Among authors: musoro jz. BMC Cancer. 2021 Oct 7;21(1):1083. doi: 10.1186/s12885-021-08609-7. BMC Cancer. 2021. PMID: 34620124 Free PMC article.
Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IVB mycosis fungoides/Sézary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT).
Stadler R, Romero PO, Bagot M, Quaglino P, Guenova E, Jonak C, Papadavid E, Stranzenbach R, Sartori D, Musoro JZ, Falato C, Marreaud S, Scarisbrick JJ, Knobler R. Stadler R, et al. Among authors: musoro jz. Eur J Cancer. 2021 Oct;156 Suppl 1:S22-S23. doi: 10.1016/S0959-8049(21)00668-7. Eur J Cancer. 2021. PMID: 34649647 No abstract available.
24 results